ERBB2 and breast carcinoma: According to guidelines of the American Society of Clinical Oncology (2018), breast cancer is HER2-positive if an analysis of biopsy samples from tumours shows 3+ staining by immunohistochemistry (IHC) or ERBB2 gene amplification of six or more copies via in situ hybridization (ISH) tests [8].